Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer

McGahan, L
Record ID 32017000331
English
Authors' recommendations: Overall, ceritinib increased PFS and duration of response in untreated ALK-positive NSCLC, regardless of the presence or absence of baseline BM, relative to platinum-based chemotherapy. Ceritinib also improved general QoL and prolonged time to deterioration of cancer-specific symptoms compared to chemotherapy. However, results from the ASCEND-4 (phase III) open-label, randomised, multicentre trial hold limited external validity as crizotinib is now standard care over chemotherapy for ALK-positive NSCLC and it is unclear whether increased PFS actually confers a meaningful change in OS. Comparative studies of other second- and third-generation ALK inhibitors are ongoing which may offer further first-line options.
Details
Project Status: Completed
URL for project: http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published: 2017
URL for published report: http://eprints.hta.lbg.ac.at/1123/1/DSD_HSO_Nr.69.pdf
URL for additional information: http://eprints.hta.lbg.ac.at/1123/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Anaplastic Lymphoma Kinase
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.